Hot off the press! The 2Q11 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!

The 2Q11 OnBioVC Trend Analysis tracked, in aggregate, 80 biopharma, diagnostic, device, medical- IT and biofuel venture financings totaling $1,896.3M. Compared to 2Q10 OnBioVC data, this investment activity represents a decrease in the number of quarter-over-quarter financings by 1 (80 v. 81) and an increase in quarter-over-quarter total invested capital of $232.1M ($1,896.3M v. $1,664.2M). 2Q11 total venture financings yielded the highest aggregate dollars of life science risk capital put to work since the $2,103.6M in 1Q08. A robust activity growth trend has emerged since the 4Q10 floor was installed, leaving the twelve-month ‘11 run-rate now set at $6,146.0M.

Many thanks to our wonderful partners, please show them your support!

Apredica – Preclinical ADME Tox Contract Research
Colorado Bioscience Association – Advocacy. Representation. Service.
San Jose BioCenter – Giving emerging companies that Big Company Advantage…
Headwaters | MB – Independent middle market investment bank
Freestone Group – Integrated Solutions for Emerging Life Science
Lockton – Lifescience Industry Specific Insurance Needs
Clinipace Worldwide – A Full Spectrum of Regulatory Affairs and Quality Assurance Solutions
CID4 – Accelerating the Colorado bioscience ecosystem
BioBeers – Where Great Minds Drink Alike…

_________________________________________________________________________

Sign up [HERE] for FREE Subscriptions to ‘Pharmaceutical Executive’ and ‘Life Science Leader’ Magazines (and other journals too!)